<?xml version="1.0" encoding="UTF-8"?>
<p>There are hundreds of clinical trials for SARS-CoV-2 therapies currently under way, and many involve drugs previously used against SARS-CoV and MERS-CoV [
 <xref rid="R24" ref-type="bibr">24</xref>]. Preliminary studies conducted on patients with COVID-19 show that early treatment with antivirals can reduce patient mortality, while late-stage treatment does not improve survival [
 <xref rid="R8" ref-type="bibr">8</xref>,
 <xref rid="R9" ref-type="bibr">9</xref>]. The biphasic nature of COVID-19, as already shown in SARS [
 <xref rid="R6" ref-type="bibr">6</xref>,
 <xref rid="R7" ref-type="bibr">7</xref>], could explain why treatments with antiviral drugs are useful just during the first phase of the disease.
</p>
